Viewing nowGabanyuro Capsule 50 mg (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
Hanlim Pharmaceutical Co., Ltd.

MFDS item code 201901392 · Approved 2019.03.07 · Insurance code 645306080
Treatment of neuropathic pain and partial-onset seizures; treatment of fibromyalgia
This drug is used for the relief of peripheral and central neuropathic pain in adults and is also utilized as an adjunctive therapy for partial seizures in epilepsy patients. Additionally, it is effective in alleviating symptoms of fibromyalgia. It helps to control pain and prevent seizures, thereby improving the quality of life of patients.
This medication is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with renal impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medication may be 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose of this medication may be 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation.”) 2. Epilepsy Adults: The starting dose of this medication may be 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, this medication should be discontinued gradually over at least 1 week. 5. Patients with renal impairment In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after each 4-hour hemodialysis session. ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: An additional dose refers to a dose administered once as a supplement. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This drug may increase the risk of suicidal thoughts or behaviors, therefore it is essential to closely monitor for depression or mood changes during treatment. This drug should not be used by individuals with allergies to the ingredients or by patients with certain genetic lactose intolerance. Diabetic patients should be cautious as weight gain may require adjustments in blood sugar control medication doses. If severe allergic reactions such as angioedema occur, discontinue use immediately. Elderly patients should be cautious as this medication may increase the risk of falls or injuries due to dizziness or drowsiness. Some patients may experience blurred vision or changes in sight, and should consult a physician if such symptoms occur. Discontinuing this drug abruptly may lead to withdrawal symptoms such as insomnia, headache, nausea, anxiety, so dosage should be gradually reduced as directed by a physician. Patients with a history of drug abuse or mental illness may have a risk of misuse or dependence on this medication and should take it carefully. Patients with impaired kidney function may need dosage adjustments. Patients with heart disease should take caution when using this medication. Co-administration with other centrally acting CNS depressants may increase the risk of drowsiness or respiratory depression, hence caution is advised. During the early stages of pregnancy, there may be a risk of fetal malformation; therefore, women who are pregnant or planning to become pregnant should consult a physician before use and employ effective contraception. Nursing women should discuss with their doctor whether to discontinue breastfeeding or the medication, as this drug may be transmitted through breast milk. Before driving or operating hazardous machinery, confirm if the medication causes dizziness or drowsiness, and avoid such activities if symptoms are present. In cases of overdose, symptoms such as confusion, drowsiness, depression, or seizures may arise, necessitating immediate medical attention and possible hemodialysis treatment. This medication should be kept out of the reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture. A cool place with a temperature between 15 to 30 degrees Celsius is suitable for storage.
A hard capsule with a navy blue upper part and a white lower part containing white or pale yellow powder.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Hard capsule · Prescription medication
Hanlim Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.